| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1091282182 |
| P356 | DOI | 10.1038/NBT.3948 |
| P698 | PubMed publication ID | 28829437 |
| P2093 | author name string | Meena | |
| Gregory L Verdine | |||
| Nenad Svrzikapa | |||
| Ivan Zlatev | |||
| Luciano H Apponi | |||
| Dinah W Y Sah | |||
| Susovan Mohapatra | |||
| Naoki Iwamoto | |||
| Stephany M Standley | |||
| Chandra Vargeese | |||
| David C D Butler | |||
| Genliang Lu | |||
| Jason Jingxin Zhang | |||
| Maria Frank-Kamenetsky | |||
| P2860 | cites work | Stereodefined phosphorothioate analogues of DNA: relative thermodynamic stability of the model PS-DNA/DNA and PS-DNA/RNA complexes | Q78345501 |
| Effects of hemolysis interferences on routine biochemistry parameters | Q82805197 | ||
| Directed Arbuzov-type reactions of 2-cyano-1,1-dimethylethyl deoxynucleoside phosphites | Q82844681 | ||
| Stereocontrolled synthesis of oligoribonucleoside phosphorothioates by an oxazaphospholidine approach | Q83215974 | ||
| Stereocontrolled solid-phase synthesis of phosphorothioate oligoribonucleotides using 2'-O-(2-cyanoethoxymethyl)-nucleoside 3'-O-oxazaphospholidine monomers | Q84892932 | ||
| Structure of human RNase H1 complexed with an RNA/DNA hybrid: insight into HIV reverse transcription | Q27648911 | ||
| Genetic therapies for RNA mis-splicing diseases | Q28235690 | ||
| Silencing disease genes in the laboratory and the clinic | Q29039090 | ||
| Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). | Q33910842 | ||
| Molecular mechanisms of action of antisense drugs | Q33916100 | ||
| Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages. | Q34448026 | ||
| Human RNase H1 discriminates between subtle variations in the structure of the heteroduplex substrate | Q34572249 | ||
| Novel route to oligo(deoxyribonucleoside phosphorothioates). Stereocontrolled synthesis of P-chiral oligo(deoxyribonucleoside phosphorothioates). | Q34607993 | ||
| RNAi therapeutics: a potential new class of pharmaceutical drugs | Q36654918 | ||
| Stereocontrolled synthesis of oligonucleotide analogs containing chiral internucleotidic phosphorus atoms. | Q37896490 | ||
| Designing chemically modified oligonucleotides for targeted gene silencing | Q38037797 | ||
| Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. | Q38046628 | ||
| Phosphorothioates, essential components of therapeutic oligonucleotides | Q38263580 | ||
| Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides | Q38289791 | ||
| Stereodifferentiation--the effect of P chirality of oligo(nucleoside phosphorothioates) on the activity of bacterial RNase H. | Q40397106 | ||
| Stereo-enriched phosphorothioate oligodeoxynucleotides: synthesis, biophysical and biological properties | Q40857624 | ||
| Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. | Q41846059 | ||
| Stereochemical bias introduced during RNA synthesis modulates the activity of phosphorothioate siRNAs | Q42147092 | ||
| Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals | Q42719353 | ||
| Efficient Synthesis and Biological Evaluation of 5'-GalNAc Conjugated Antisense Oligonucleotides | Q44320144 | ||
| Stereocontrolled solid-phase synthesis of oligonucleoside H-phosphonates by an oxazaphospholidine approach | Q46263566 | ||
| Solid-phase synthesis of stereoregular oligodeoxyribonucleoside phosphorothioates using bicyclic oxazaphospholidine derivatives as monomer units. | Q46267628 | ||
| P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides | Q47939598 | ||
| Rapid HATU-Mediated Solution Phase siRNA Conjugation | Q60450276 | ||
| Deoxyribonucleoside CyclicN-Acylphosphoramidites as a New Class of Monomers for the Stereocontrolled Synthesis of Oligothymidylyl- and Oligodeoxycytidylyl- Phosphorothioates | Q62028998 | ||
| Hypertriglyceridemic mice transgenic for the human apolipoprotein C-III gene are neither insulin resistant nor hyperinsulinemic | Q72153042 | ||
| Stability of stereoregular oligo(nucleoside phosphorothioate)s in human plasma: diastereoselectivity of plasma 3'-exonuclease | Q73120671 | ||
| Stereodependent inhibition of plasminogen activator inhibitor type 1 by phosphorothioate oligonucleotides: proof of sequence specificity in cell culture and in vivo rat experiments | Q74122697 | ||
| Solid-phase stereoselective synthesis of 2'-O-methyl-oligoribonucleoside phosphorothioates using nucleoside bicyclic oxazaphospholidines | Q77749372 | ||
| P433 | issue | 9 | |
| P304 | page(s) | 845-851 | |
| P577 | publication date | 2017-08-21 | |
| P1433 | published in | Nature Biotechnology | Q1893837 |
| P1476 | title | Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. | |
| P478 | volume | 35 |
| Q57025700 | A Versatile and Convenient Synthesis of S-Labeled Phosphorothioate Oligonucleotides |
| Q90465691 | A gene-edited mouse model of limb-girdle muscular dystrophy 2C for testing exon skipping |
| Q98386176 | Advances in oligonucleotide drug delivery |
| Q64096491 | Antisense oligonucleotides: A primer |
| Q47344432 | Antisense oligonucleotides: the next frontier for treatment of neurological disorders |
| Q92694341 | Arylation of Axially Chiral Phosphorothioate Salts by Dinuclear PdI Catalysis |
| Q92580496 | Chemical methods for the modification of RNA |
| Q48569299 | Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs |
| Q90428489 | Enhanced affinity of racemic phosphorothioate DNA with transcription factor SATB1 arising from diastereomer-specific hydrogen bonds and hydrophobic contacts |
| Q52685687 | Huntington’s Disease Clinical Trials Corner: February 2018 |
| Q64994264 | Investigation of factors influencing the separation of diastereomers of phosphorothioated oligonucleotides. |
| Q92677827 | Metabolite Profiling of the Antisense Oligonucleotide Eluforsen Using Liquid Chromatography-Mass Spectrometry |
| Q91931912 | Mind the gap! |
| Q90279052 | Molecular Dynamics Study of the Hybridization between RNA and Modified Oligonucleotides |
| Q60909992 | Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges |
| Q91594164 | Muscular dystrophies |
| Q90743959 | Nuclear and Cytoplasmatic Quantification of Unconjugated, Label-Free Locked Nucleic Acid Oligonucleotides |
| Q92868511 | Overexpression of ZEB2-AS1 promotes epithelial-to-mesenchymal transition and metastasis by stabilizing ZEB2 mRNA in head neck squamous cell carcinoma |
| Q49952684 | RNA-based therapeutics: Increasing efficacy |
| Q64228902 | Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches |
| Q48195315 | Stereochemical Sequence Dictates Unimolecular Diblock Copolymer Assembly |
| Q64443413 | Synthesis and biophysical properties of carbamate-locked nucleic acid (LNA) oligonucleotides with potential antisense applications |
| Q64094354 | Targeting RNA : A Transformative Therapeutic Strategy |
| Q92209450 | The current state and future directions of RNAi-based therapeutics |
| Q92419746 | Therapeutic developments for Duchenne muscular dystrophy |
| Q96609193 | Therapeutic siRNA: state of the art |
| Q92933262 | Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides |
| Q64936100 | Unlocking P(V): Reagents for chiral phosphorothioate synthesis. |
Search more.